An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma

NCT00880061 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

NIH

Sponsor class

Conditions

Brain Neoplasm
Glioma

Interventions

DRUG: IL13-PE38QQR

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)